US FDA approval for generic Zetia® tablets

Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 020. India FOR IMMEDIATE RELEASE Sun Pharma announces US FDA approval for generic Zetia ® tablets Mumbai, June 13, 2017: Sun Pharmaceutical Industrie s Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and inclu des its subsidiaries or associate companies) today announced that one of its wholly owned subsid iaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Zetia ®, (ezetimibe) Tablets 10mg. These generic ezetimibe tablets are therapeutic equ ivalents of Merck’s Zetia ® tablets. As per IMS, ezetimibe tablets had annual sales of approximately US$2.7 billion in the US for the 12 months ended April 2017. ® - All brand names and trademarks are the property of respective owners. Disclaimer: Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top phar maceutical company. A vertically integrated business, economie s of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable p rices. It provides high-quality, affordable medicin es trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is support ed by 42 manufacturing facilities spread across 6 continents , R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the com pany enjoys leadership across 11 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging mark ets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 3 global markets. Its API business footpr int is strengthened through 14 world class API manu facturing facilities across the globe. Sun Pharma fosters exc ellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investmen ts of approximately 8% of annual revenues. For furt her information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live Contacts Nimish Desai Frederick Castro Tel +91 22 4324 4324, Xtn 2778 Tel +91 22 4324 4324, Xtn 2777 Tel Direct +91 22 4324 2778 Tel Direct +91 22 4324 2777 Mobile +91 -98203 30182 Mobile +91 99206 65176 E mail [email protected] E mail frederick [email protected]

The release as fetched from its publisher. sunpharma.com ↗